Prise en charge des cancers du cavum (rhinopharynx)

Pauline Jardel; Juliette Thariat; Pierre Blanchard; Fatma Elloumi; Nabil Toumi; René Jean Bensadoun; Mounir Frikha; Jamel Daoud; Jean Bourhis

doi:10.1684/bdc.2014.1964

Prise en charge des cancers du cavum (rhinopharynx)

Translated title of the contribution: Nasopharyngeal cancers, an overview

Pauline Jardel, Juliette Thariat, Pierre Blanchard, Fatma Elloumi, Nabil Toumi, René Jean Bensadoun, Mounir Frikha, Jamel Daoud, Jean Bourhis

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Cancer of the nasopharynx is an uncommon malignancy in France (incidence = 0.5/year/100,000 men) but is endemic in areas like in South-East Asia. Exclusive radiation therapy used to be the standard and results in local control rates for T3-T4 tumors around 50-75%. Intensity-modulated radiotherapy (IMRT) improves tumor coverage with a sparing of organs at risk and has to be privileged. Concurrent chemotherapy with IMRT achieved significant survival benefice with 5-year overall survival above 75%. Concurrent radiochemotherapy with platinium is the most frequent scheme but induction and adjuvant chemotherapies are discussed to reduce distant failure: studies are currently ongoing. Follow-up aims to detect early local failures with a chance of cure and to manage long-term toxicities.

Translated title of the contribution	Nasopharyngeal cancers, an overview
Original language	French
Pages (from-to)	445-454
Number of pages	10
Journal	Bulletin du Cancer
Volume	101
Issue number	5
DOIs	https://doi.org/10.1684/bdc.2014.1964
Publication status	Published - 1 Jan 2014

Access to Document

10.1684/bdc.2014.1964

Cite this

@article{5c154a47bca8439691384946da141079,

title = "Prise en charge des cancers du cavum (rhinopharynx)",

abstract = "Cancer of the nasopharynx is an uncommon malignancy in France (incidence = 0.5/year/100,000 men) but is endemic in areas like in South-East Asia. Exclusive radiation therapy used to be the standard and results in local control rates for T3-T4 tumors around 50-75%. Intensity-modulated radiotherapy (IMRT) improves tumor coverage with a sparing of organs at risk and has to be privileged. Concurrent chemotherapy with IMRT achieved significant survival benefice with 5-year overall survival above 75%. Concurrent radiochemotherapy with platinium is the most frequent scheme but induction and adjuvant chemotherapies are discussed to reduce distant failure: studies are currently ongoing. Follow-up aims to detect early local failures with a chance of cure and to manage long-term toxicities.",

keywords = "Chemotherapy, IMRT, Nasopharyngeal cancer, Radiation therapy",

author = "Pauline Jardel and Juliette Thariat and Pierre Blanchard and Fatma Elloumi and Nabil Toumi and Bensadoun, {Ren{\'e} Jean} and Mounir Frikha and Jamel Daoud and Jean Bourhis",

year = "2014",

month = jan,

day = "1",

doi = "10.1684/bdc.2014.1964",

language = "Fran{\c c}ais",

volume = "101",

pages = "445--454",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "5",

}

TY - JOUR

T1 - Prise en charge des cancers du cavum (rhinopharynx)

AU - Jardel, Pauline

AU - Thariat, Juliette

AU - Blanchard, Pierre

AU - Elloumi, Fatma

AU - Toumi, Nabil

AU - Bensadoun, René Jean

AU - Frikha, Mounir

AU - Daoud, Jamel

AU - Bourhis, Jean

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cancer of the nasopharynx is an uncommon malignancy in France (incidence = 0.5/year/100,000 men) but is endemic in areas like in South-East Asia. Exclusive radiation therapy used to be the standard and results in local control rates for T3-T4 tumors around 50-75%. Intensity-modulated radiotherapy (IMRT) improves tumor coverage with a sparing of organs at risk and has to be privileged. Concurrent chemotherapy with IMRT achieved significant survival benefice with 5-year overall survival above 75%. Concurrent radiochemotherapy with platinium is the most frequent scheme but induction and adjuvant chemotherapies are discussed to reduce distant failure: studies are currently ongoing. Follow-up aims to detect early local failures with a chance of cure and to manage long-term toxicities.

AB - Cancer of the nasopharynx is an uncommon malignancy in France (incidence = 0.5/year/100,000 men) but is endemic in areas like in South-East Asia. Exclusive radiation therapy used to be the standard and results in local control rates for T3-T4 tumors around 50-75%. Intensity-modulated radiotherapy (IMRT) improves tumor coverage with a sparing of organs at risk and has to be privileged. Concurrent chemotherapy with IMRT achieved significant survival benefice with 5-year overall survival above 75%. Concurrent radiochemotherapy with platinium is the most frequent scheme but induction and adjuvant chemotherapies are discussed to reduce distant failure: studies are currently ongoing. Follow-up aims to detect early local failures with a chance of cure and to manage long-term toxicities.

KW - Chemotherapy

KW - IMRT

KW - Nasopharyngeal cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84903136395&partnerID=8YFLogxK

U2 - 10.1684/bdc.2014.1964

DO - 10.1684/bdc.2014.1964

M3 - Article

C2 - 24886895

AN - SCOPUS:84903136395

SN - 0007-4551

VL - 101

SP - 445

EP - 454

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 5

ER -

Prise en charge des cancers du cavum (rhinopharynx)

Abstract

Access to Document

Other files and links

Cite this